» Articles » PMID: 24305921

Prognostic Significance of the Number of Metastatic Lymph Nodes to Stratify the Risk of Recurrence

Overview
Journal World J Surg
Publisher Wiley
Specialty General Surgery
Date 2013 Dec 6
PMID 24305921
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prophylactic dissection facilitates identification of central lymph node (LN) metastasis in patients with papillary thyroid cancer (PTC). Because most staging systems do not stratify risks by the number of LN metastases, postoperative treatments vary among different institutions. Therefore we investigated the significance of number of LN metastases in risk stratification for recurrence in PTC.

Material And Methods: A retrospective review was performed for 3,305 patients who had undergone thyroidectomy at Ajou University Hospital. A total of 2,462 patients (73.5 %) underwent total thyroidectomy, and another 3,152 (94.1 %) underwent central LN dissection. Lateral cervical LN dissection had been performed in 420 patients (12.5 %).

Results: There were 115 patients with recurrence (3.4 %). Recurrence-free rates were 94.6 % at 5 years and 89.4 % at 10 years. On univariate analysis, prognostic factors for recurrence were extent of thyroidectomy, tumor size, capsular invasion, T stage, N stage, number of LN metastasis, TNM stage, and radioactive iodine (RAI) therapy. On multivariate analysis, number of LN metastasis and N stage were significant prognostic factors for recurrence. Recurrence-free rate was significantly different between patients with 0-1 LN and those with 2 or more LN.

Conclusions: Number of metastatic LN was a significant prognostic factor, in addition to the N stage. Therefore, number of metastatic LN must be considered for postoperative staging system to tailor treatment and follow-up recommendations. In addition, patients with ≥2 metastatic LN may benefit from total thyroidectomy and RAI therapy with postoperative follow-up with serum thyroglobulin.

Citing Articles

Analysis of the prognostic value of thyroglobulin antibody change trends during follow-up after I treatment in patients with differentiated thyroid carcinoma.

Ge H, Chen W, Lin Z, Li Y, Chen S Front Oncol. 2025; 15:1496594.

PMID: 39968066 PMC: 11832372. DOI: 10.3389/fonc.2025.1496594.


Aggressive variants of papillary thyroid carcinoma: characteristics, influencing factors, and effectiveness of radioiodine therapy.

Deng Y, Pan L, Xu Y, Duan Y, Chen E, Luo Y J Endocrinol Invest. 2024; .

PMID: 39652145 DOI: 10.1007/s40618-024-02507-y.


Impact of nodal status evaluation on therapeutic strategy for clinically unifocal T1b/small T2 node negative papillary thyroid carcinoma.

Laurino A, Pennestri F, Procopio P, Martullo A, Santoro G, Gallucci P Endocrine. 2024; 87(3):1070-1079.

PMID: 39557746 DOI: 10.1007/s12020-024-04101-x.


Nomogram for predicting 10-year postoperative recurrence of stage I gastric cancer.

Lyu T, Luo M, Hu H Transl Cancer Res. 2024; 13(10):5497-5508.

PMID: 39525020 PMC: 11543093. DOI: 10.21037/tcr-24-692.


Factors associated with occult lateral lymph node metastases in patients with clinically lymph node negative papillary thyroid carcinoma: a systematic review and meta-analysis.

Fei Y, Wang B, Yao X, Wu J Front Endocrinol (Lausanne). 2024; 15:1353923.

PMID: 39493782 PMC: 11527613. DOI: 10.3389/fendo.2024.1353923.


References
1.
Goretzki P, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M . Surgical reintervention for differentiated thyroid cancer. Br J Surg. 1993; 80(8):1009-12. DOI: 10.1002/bjs.1800800826. View

2.
Eustatia-Rutten C, Smit J, Romijn J, van der Kleij-Corssmit E, Pereira A, Stokkel M . Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf). 2004; 61(1):61-74. DOI: 10.1111/j.1365-2265.2004.02060.x. View

3.
Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl D, Bidart J . Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005; 90(10):5723-9. DOI: 10.1210/jc.2005-0285. View

4.
Noguchi S, Noguchi A, Murakami N . Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer. 1970; 26(5):1053-60. DOI: 10.1002/1097-0142(197011)26:5<1053::aid-cncr2820260513>3.0.co;2-x. View

5.
Mazzaferri E, Jhiang S . Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97(5):418-28. DOI: 10.1016/0002-9343(94)90321-2. View